Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $92,364.06 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now owns 7,000 shares of the company’s stock, valued at approximately $296,310. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $46.53 on Friday. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $65.60. The stock’s 50 day simple moving average is $42.58 and its 200-day simple moving average is $43.95.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business’s revenue for the quarter was up 709.1% on a year-over-year basis. As a group, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Institutional Trading of Janux Therapeutics

Large investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after purchasing an additional 34,069 shares during the last quarter. Vanguard Group Inc. lifted its position in Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares in the last quarter. Logos Global Management LP boosted its stake in Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after buying an additional 600,000 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Janux Therapeutics in the 1st quarter valued at $20,420,000. Finally, Samlyn Capital LLC increased its stake in shares of Janux Therapeutics by 9.6% in the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock worth $13,602,000 after acquiring an additional 28,312 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Scotiabank dropped their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus began coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research report on Monday, August 19th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $66.13.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.